Methods for treating brain metastasis
The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
1. A method for treating a cancer that has metastasized to the brain in a subject, comprising: administering to the subject tonabersat.
2. The method of claim 1 , wherein the tonabersat is administered in an amount of about 10 mg/kg.
3. The method of claim 1 , wherein the tonabersat is administered in an amount of between about 0.8 mg/kg and about 1.2 mg/kg.
4. The method of claim 1 , wherein the cancer is a breast cancer or a lung cancer.
5. The method of claim 1 , further comprising administering to the subject an anti-cancer agent.
6. The method of claim 5 , wherein the anti-cancer agent is carboplatin.
7. The method of claim 6 , wherein the carboplatin is administered in an amount of between 4 mg/kg and about 6 mg/kg.
8. A method for preventing and/or inhibiting the metastasis of a cancer to the brain in a subject, comprising: administering to the subject tonabersat.
9. The method of claim 8 , wherein the tonabersat is administered in an amount of about 10 mg/kg.
10. The method of claim 8 , wherein the tonabersat is administered in an amount of between about 0.8 mg/kg and about 1.2 mg/kg.
11. The method of claim 8 , wherein the cancer is a breast cancer or a lung cancer.
12. The method of claim 8 , further comprising administering to the subject an anti-cancer agent.
13. The method of claim 12 , wherein the anti-cancer agent is carboplatin.
14. The method of claim 13 , wherein the carboplatin is administered in an amount of between 4 mg/kg and about 6 mg/kg.
15. A method for reducing the risk of the metastasis of a cancer to the brain in a subject, comprising: administering to the subject tonabersat.
16. The method of claim 15 , wherein tonabersat is administered in an amount of about 10 mg/kg.
17. The method of claim 15 , wherein the tonabersat is administered in an amount of between about 0.8 mg/kg and about 1.2 mg/kg.
18. The method of claim 15 , wherein the cancer is a breast cancer or a lung cancer.
19. The method of claim 15 , further comprising administering to the subject an anti-cancer agent.
20. The method of claim 19 , wherein the anti-cancer agent is carboplatin.